Literature DB >> 27099320

Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.

Ivy Widjaja1,2, Oliver Wicht3, Willem Luytjes3, Kees Leenhouts2, Peter J M Rottier4, Frank J M van Kuppeveld4, Bert Jan Haijema2, Cornelis A M de Haan1.   

Abstract

UNLABELLED: Antibodies against the fusion (F) protein of respiratory syncytial virus (RSV) play an important role in the protective immune response to this important respiratory virus. Little is known, however, about antibody levels against multiple F-specific epitopes induced by infection or after vaccination against RSV, while this is important to guide the evaluation of (novel) vaccines. In this study, we analyzed antibody levels against RSV proteins and F-specific epitopes in human sera and in sera of vaccinated and experimentally infected cotton rats and the correlation thereof with virus neutralization. Analysis of human sera revealed substantial diversity in antibody levels against F-, G (attachment)-, and F-specific epitopes between individuals. The highest correlation with virus neutralization was observed for antibodies recognizing prefusion-specific antigenic site Ø. Nevertheless, our results indicate that high levels of antibodies targeting other parts of the F protein can also mediate a potent antiviral antibody response. In agreement, sera of experimentally infected cotton rats contained high neutralizing activity despite lacking antigenic site Ø-specific antibodies. Strikingly, vaccination with formalin-inactivated RSV (FI-RSV) exclusively resulted in the induction of poorly neutralizing antibodies against postfusion-specific antigenic site I, although antigenic sites I, II, and IV were efficiently displayed in FI-RSV. The apparent immunodominance of antigenic site I in FI-RSV likely explains the low levels of neutralizing antibodies upon vaccination and challenge and may play a role in the vaccination-induced enhancement of disease observed with such preparations. IMPORTANCE: RSV is an importance cause of hospitalization of infants. The development of a vaccine against RSV has been hampered by the disastrous results obtained with FI-RSV vaccine preparations in the 1960s that resulted in vaccination-induced enhancement of disease. To get a better understanding of the antibody repertoire induced after infection or after vaccination against RSV, we investigated antibody levels against fusion (F) protein, attachment (G) protein, and F-specific epitopes in human and animal sera. The results indicate the importance of prefusion-specific antigenic site Ø antibodies as well as of antibodies targeting other epitopes in virus neutralization. However, vaccination of cotton rats with FI-RSV specifically resulted in the induction of weakly neutralizing, antigenic site I-specific antibodies, which may play a role in the enhancement of disease observed after vaccination with such preparations.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27099320      PMCID: PMC4907225          DOI: 10.1128/JVI.00235-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Serum antibody decay in adults following natural respiratory syncytial virus infection.

Authors:  Ann R Falsey; Harjot K Singh; Edward E Walsh
Journal:  J Med Virol       Date:  2006-11       Impact factor: 2.327

2.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.

Authors:  Davide Corti; Siro Bianchi; Fabrizia Vanzetta; Andrea Minola; Laurent Perez; Gloria Agatic; Barbara Guarino; Chiara Silacci; Jessica Marcandalli; Benjamin J Marsland; Antonio Piralla; Elena Percivalle; Federica Sallusto; Fausto Baldanti; Antonio Lanzavecchia
Journal:  Nature       Date:  2013-08-18       Impact factor: 49.962

3.  Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer.

Authors:  Supranee Chaiwatpongsakorn; Raquel F Epand; Peter L Collins; Richard M Epand; Mark E Peeples
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

4.  Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.

Authors:  Margarita Magro; Vicente Mas; Keith Chappell; Mónica Vázquez; Olga Cano; Daniel Luque; María C Terrón; José A Melero; Concepción Palomo
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

5.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

Authors:  R A Olmsted; N Elango; G A Prince; B R Murphy; P R Johnson; B Moss; R M Chanock; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

6.  Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

Authors:  Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham
Journal:  Science       Date:  2013-04-25       Impact factor: 47.728

7.  Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma.

Authors:  Nandini Krishnamoorthy; Anupriya Khare; Timothy B Oriss; Mahesh Raundhal; Christina Morse; Manohar Yarlagadda; Sally E Wenzel; Martin L Moore; R Stokes Peebles; Anuradha Ray; Prabir Ray
Journal:  Nat Med       Date:  2012-09-09       Impact factor: 53.440

8.  Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation.

Authors:  Abdul S Yunus; Trent P Jackson; Katherine Crisafi; Irina Burimski; Nicole R Kilgore; Dorian Zoumplis; Graham P Allaway; Carl T Wild; Karl Salzwedel
Journal:  Virology       Date:  2009-11-18       Impact factor: 3.616

9.  Architecture of respiratory syncytial virus revealed by electron cryotomography.

Authors:  Lassi Liljeroos; Magdalena Anna Krzyzaniak; Ari Helenius; Sarah Jane Butcher
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

10.  A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.

Authors:  Anders Krarup; Daphné Truan; Polina Furmanova-Hollenstein; Lies Bogaert; Pascale Bouchier; Ilona J M Bisschop; Myra N Widjojoatmodjo; Roland Zahn; Hanneke Schuitemaker; Jason S McLellan; Johannes P M Langedijk
Journal:  Nat Commun       Date:  2015-09-03       Impact factor: 14.919

View more
  19 in total

Review 1.  Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.

Authors:  Sara A Taleb; Asmaa A Al Thani; Khalid Al Ansari; Hadi M Yassine
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-06       Impact factor: 3.267

2.  A vulnerable, membrane-proximal site in human respiratory syncytial virus F revealed by a prefusion-specific single-domain antibody.

Authors:  Iebe Rossey; Ching-Lin Hsieh; Koen Sedeyn; Marlies Ballegeer; Bert Schepens; Jason S Mclellan; Xavier Saelens
Journal:  J Virol       Date:  2021-03-10       Impact factor: 5.103

3.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

4.  Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.

Authors:  Young-Man Kwon; Youri Lee; Ki Hye Kim; Yu Jin Jung; Zhuo Li; Subbiah Jeeva; Sujin Lee; Martin L Moore; Sang-Moo Kang
Journal:  Vaccine       Date:  2019-09-18       Impact factor: 3.641

5.  Natural killer cells contribute to enhanced respiratory disease after oil-in-water emulsion adjuvanted vaccination against respiratory syncytial virus and infection.

Authors:  Yoonsuh Park; Ki-Hye Kim; Youri Lee; Young-Tae Lee; Sang-Moo Kang; Eun-Ju Ko
Journal:  Hum Vaccin Immunother       Date:  2021-04-20       Impact factor: 3.452

6.  Bottom-up de novo design of functional proteins with complex structural features.

Authors:  Che Yang; Fabian Sesterhenn; Jaume Bonet; Eva A van Aalen; Leo Scheller; Luciano A Abriata; Johannes T Cramer; Xiaolin Wen; Stéphane Rosset; Sandrine Georgeon; Theodore Jardetzky; Thomas Krey; Martin Fussenegger; Maarten Merkx; Bruno E Correia
Journal:  Nat Chem Biol       Date:  2021-01-04       Impact factor: 15.040

7.  Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of Age.

Authors:  Jop Jans; Oliver Wicht; Ivy Widjaja; Inge M L Ahout; Ronald de Groot; Teun Guichelaar; Willem Luytjes; Marien I de Jonge; Cornelis A M de Haan; Gerben Ferwerda
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

8.  In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.

Authors:  Elisabeth A van Erp; Puck B van Kasteren; Teun Guichelaar; Inge M L Ahout; Cornelis A M de Haan; Willem Luytjes; Gerben Ferwerda; Oliver Wicht
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

9.  Effects of cinnamaldehyde on anti-respiratory syncytial virus: A protocol of systematic review and meta-analysis.

Authors:  Lan Feng; Jing Li; Hai-Bo Yu; Qing Xue; Li-Juan Dai
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

10.  Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness.

Authors:  Natalie I Mazur; Nicole M Horsley; Janet A Englund; Maaike Nederend; Amalia Magaret; Azad Kumar; Shamir R Jacobino; Cornelis A M de Haan; Subarna K Khatry; Steven C LeClerq; Mark C Steinhoff; James M Tielsch; Joanne Katz; Barney S Graham; Louis J Bont; Jeanette H W Leusen; Helen Y Chu
Journal:  J Infect Dis       Date:  2019-01-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.